CD48
gene geneOn this page
Also known as BLASTmCD48hCD48SLAMF2
Summary
CD48 (CD48 molecule, HGNC:1683) is a protein-coding gene on chromosome 1q23.3, encoding CD48 antigen (P09326). Glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein that interacts via its N-terminal immunoglobulin domain with cell surface receptors including CD244/2B4 or CD2 to regulate immune cell function and activation.
This gene encodes a member of the CD2 subfamily of immunoglobulin-like receptors which includes SLAM (signaling lymphocyte activation molecules) proteins. The encoded protein is found on the surface of lymphocytes and other immune cells, dendritic cells and endothelial cells, and participates in activation and differentiation pathways in these cells. The encoded protein does not have a transmembrane domain, however, but is held at the cell surface by a GPI anchor via a C-terminal domain which maybe cleaved to yield a soluble form of the receptor. Multiple transcript variants encoding different isoforms have been found for this gene.
Source: NCBI Gene 962 — RefSeq curated summary.
At a glance
- GWAS associations: 5
- Clinical variants (ClinVar): 55 total
- GTEx eGene: eQTL in 7 tissues, sQTL in 5 (q < 0.05)
- Constraint (gnomAD): pLI 0.00 (LoF-tolerant), LOEUF 1.31 (unconstrained)
- MANE Select transcript:
NM_001778 - Interaction hub: 2,226 STRING partners (top 6% of genes corpus-wide)
- Notable: 55 clinical variants but no curated precision-oncology (CIViC) evidence yet
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:1683 |
| Approved symbol | CD48 |
| Name | CD48 molecule |
| Location | 1q23.3 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | BLAST, mCD48, hCD48, SLAMF2 |
| Ensembl gene | ENSG00000117091 |
| Ensembl biotype | protein_coding |
| OMIM | 109530 |
| Entrez | 962 |
Gene structure
Transcript identifiers
Ensembl transcripts: 12 — 9 protein_coding, 3 nonsense_mediated_decay
MANE Select: ENST00000368046
Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 3
ENST00000368046, ENST00000368045, ENST00000613788, ENST00000902592, ENST00000902593, ENST00001104357, ENST00001104358, ENST00001104359, ENST00001104360, ENST00001104361, ENST00001116597, ENST00001143569
RefSeq mRNA: 2 — MANE Select: NM_001778
NM_001256030, NM_001778
CCDS: CCDS1208, CCDS72955
Canonical transcript exons
ENST00000368046 — 4 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001166175 | 160681202 | 160681468 |
| ENSE00001166183 | 160684887 | 160685189 |
| ENSE00001446197 | 160678746 | 160679131 |
| ENSE00001920767 | 160711682 | 160711822 |
Expression profiles
Bgee: expression breadth ubiquitous, 197 present calls, max score 99.52.
FANTOM5 (CAGE): breadth broad, TPM avg 68.3544 / max 2199.8164, expressed in 460 samples.
Highest expression (Bgee): monocyte, leukocyte, mononuclear cell, granulocyte, blood.
Genetic regulation across tissues (GTEx eQTL / sQTL)
CD48 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 7 tissues and its splicing (sQTL) in 5 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.
12 significant tissue × QTL associations:
| Tissue | QTL | q-value | Slope | Lead variant |
|---|---|---|---|---|
| Whole Blood | sqtl | 4.7e-141 | +1.50 | 1:160684968:C:G |
| Spleen | sqtl | 6.9e-59 | +1.77 | 1:160684968:C:G |
| Whole Blood | eqtl | 6.7e-08 | -0.15 | 1:160704478:A:C |
| Cells EBV-transformed lymphocytes | eqtl | 2.8e-05 | +0.15 | 1:160711985:A:G |
| Cells EBV-transformed lymphocytes | sqtl | 8.2e-05 | -0.48 | 1:160684968:C:G |
| Adipose Subcutaneous | sqtl | 3.9e-03 | -1.05 | 1:160153986:C:G |
| Nerve Tibial | eqtl | 9.5e-03 | +0.23 | 1:160182592:C:T |
| Skin Sun Exposed Lower leg | eqtl | 9.5e-03 | +0.14 | 1:160689370:G:A |
| Ovary | eqtl | 1.9e-02 | +0.44 | 1:160172204:C:T |
| Small Intestine Terminal Ileum | sqtl | 2.4e-02 | +1.11 | 1:160684968:C:G |
| Stomach | eqtl | 3.8e-02 | +0.51 | 1:161154267:G:T |
| Esophagus Muscularis | eqtl | 4.6e-02 | -0.22 | 1:161086424:G:C |
FANTOM5 promoters
4 alternative TSS:
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 15527 | 57.0048 | 447 |
| 15526 | 11.1720 | 335 |
| 15528 | 0.1292 | 81 |
| 15529 | 0.0484 | 32 |
Top tissues by expression
showing 100 of 281 tissues by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| monocyte | CL:0000576 | 99.52 | gold quality |
| leukocyte | CL:0000738 | 99.52 | gold quality |
| mononuclear cell | CL:0000842 | 99.52 | gold quality |
| granulocyte | CL:0000094 | 99.48 | gold quality |
| blood | UBERON:0000178 | 98.19 | gold quality |
| bone marrow cell | CL:0002092 | 98.06 | gold quality |
| vermiform appendix | UBERON:0001154 | 97.83 | gold quality |
| spleen | UBERON:0002106 | 97.83 | gold quality |
| lymph node | UBERON:0000029 | 97.40 | gold quality |
| bone marrow | UBERON:0002371 | 97.39 | gold quality |
| caecum | UBERON:0001153 | 94.54 | gold quality |
| colonic epithelium | UBERON:0000397 | 93.82 | gold quality |
| epithelium of nasopharynx | UBERON:0001951 | 92.38 | gold quality |
| rectum | UBERON:0001052 | 92.37 | gold quality |
| trabecular bone tissue | UBERON:0002483 | 92.27 | gold quality |
| gall bladder | UBERON:0002110 | 91.59 | gold quality |
| periodontal ligament | UBERON:0008266 | 90.15 | gold quality |
| thymus | UBERON:0002370 | 88.97 | gold quality |
| tonsil | UBERON:0002372 | 87.71 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 87.56 | gold quality |
| superficial temporal artery | UBERON:0001614 | 87.11 | gold quality |
| small intestine Peyer’s patch | UBERON:0003454 | 86.89 | gold quality |
| mucosa of transverse colon | UBERON:0004991 | 86.41 | gold quality |
| small intestine | UBERON:0002108 | 85.46 | gold quality |
| upper lobe of left lung | UBERON:0008952 | 84.89 | gold quality |
| decidua | UBERON:0002450 | 84.14 | silver quality |
| upper lobe of lung | UBERON:0008948 | 83.81 | gold quality |
| duodenum | UBERON:0002114 | 83.01 | gold quality |
| right lung | UBERON:0002167 | 82.61 | gold quality |
| jejunal mucosa | UBERON:0000399 | 82.44 | gold quality |
| lung | UBERON:0002048 | 81.81 | gold quality |
| mucosa of urinary bladder | UBERON:0001259 | 81.33 | silver quality |
| mucosa of sigmoid colon | UBERON:0004993 | 81.20 | gold quality |
| right coronary artery | UBERON:0001625 | 80.81 | gold quality |
| colonic mucosa | UBERON:0000317 | 80.36 | gold quality |
| ileal mucosa | UBERON:0000331 | 79.61 | silver quality |
| omental fat pad | UBERON:0010414 | 79.60 | gold quality |
| peritoneum | UBERON:0002358 | 79.55 | gold quality |
| adipose tissue of abdominal region | UBERON:0007808 | 79.34 | gold quality |
| intestine | UBERON:0000160 | 78.49 | gold quality |
| transverse colon | UBERON:0001157 | 78.32 | gold quality |
| palpebral conjunctiva | UBERON:0001812 | 77.90 | gold quality |
| smooth muscle tissue | UBERON:0001135 | 77.13 | gold quality |
| buccal mucosa cell | CL:0002336 | 76.72 | silver quality |
| urinary bladder | UBERON:0001255 | 76.47 | gold quality |
| large intestine | UBERON:0000059 | 76.45 | gold quality |
| pylorus | UBERON:0001166 | 75.97 | gold quality |
| oral cavity | UBERON:0000167 | 75.94 | gold quality |
| colon | UBERON:0001155 | 75.86 | gold quality |
| right lobe of liver | UBERON:0001114 | 75.52 | gold quality |
| jejunum | UBERON:0002115 | 75.20 | gold quality |
| skin of hip | UBERON:0001554 | 74.97 | gold quality |
| calcaneal tendon | UBERON:0003701 | 74.94 | gold quality |
| nasal cavity epithelium | UBERON:0005384 | 74.70 | gold quality |
| amniotic fluid | UBERON:0000173 | 74.66 | gold quality |
| body of stomach | UBERON:0001161 | 74.65 | gold quality |
| lower lobe of lung | UBERON:0008949 | 74.60 | silver quality |
| adipose tissue | UBERON:0001013 | 74.49 | gold quality |
| liver | UBERON:0002107 | 74.38 | gold quality |
| connective tissue | UBERON:0002384 | 74.19 | gold quality |
| stomach | UBERON:0000945 | 74.01 | gold quality |
| nasal cavity mucosa | UBERON:0001826 | 73.92 | gold quality |
| fundus of stomach | UBERON:0001160 | 73.60 | gold quality |
| minor salivary gland | UBERON:0001830 | 73.48 | gold quality |
| epithelial cell of pancreas | CL:0000083 | 73.39 | gold quality |
| cardia of stomach | UBERON:0001162 | 73.20 | gold quality |
| olfactory segment of nasal mucosa | UBERON:0005386 | 72.97 | gold quality |
| subcutaneous adipose tissue | UBERON:0002190 | 72.86 | gold quality |
| saliva-secreting gland | UBERON:0001044 | 72.74 | gold quality |
| mammary duct | UBERON:0001765 | 72.74 | silver quality |
| adult organism | UBERON:0007023 | 72.57 | silver quality |
| pleura | UBERON:0000977 | 72.54 | gold quality |
| C1 segment of cervical spinal cord | UBERON:0006469 | 72.54 | gold quality |
| germinal epithelium of ovary | UBERON:0001304 | 72.50 | silver quality |
| left uterine tube | UBERON:0001303 | 72.44 | gold quality |
| descending thoracic aorta | UBERON:0002345 | 72.29 | gold quality |
| coronary artery | UBERON:0001621 | 72.26 | gold quality |
| superior surface of tongue | UBERON:0007371 | 72.08 | gold quality |
| left coronary artery | UBERON:0001626 | 72.00 | gold quality |
| parietal pleura | UBERON:0002400 | 71.99 | gold quality |
| mouth mucosa | UBERON:0003729 | 71.89 | gold quality |
| uterine cervix | UBERON:0000002 | 71.73 | gold quality |
| esophagus mucosa | UBERON:0002469 | 71.41 | gold quality |
| trachea | UBERON:0003126 | 71.36 | silver quality |
| spinal cord | UBERON:0002240 | 71.24 | gold quality |
| thoracic aorta | UBERON:0001515 | 71.17 | gold quality |
| ascending aorta | UBERON:0001496 | 71.15 | gold quality |
| vagina | UBERON:0000996 | 71.12 | gold quality |
| prostate gland | UBERON:0002367 | 70.91 | gold quality |
| right uterine tube | UBERON:0001302 | 70.80 | gold quality |
| myocardium | UBERON:0002349 | 70.68 | gold quality |
| visceral pleura | UBERON:0002401 | 70.65 | gold quality |
| thoracic mammary gland | UBERON:0005200 | 70.44 | gold quality |
| fallopian tube | UBERON:0003889 | 70.33 | gold quality |
| mammary gland | UBERON:0001911 | 70.30 | gold quality |
| upper leg skin | UBERON:0004262 | 70.28 | gold quality |
| right lobe of thyroid gland | UBERON:0001119 | 70.15 | gold quality |
| vena cava | UBERON:0004087 | 69.91 | gold quality |
| ectocervix | UBERON:0012249 | 69.87 | gold quality |
| esophagus | UBERON:0001043 | 69.82 | gold quality |
Single-cell (SCXA)
Detected in 16 experiment(s), a significant marker in 16.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-HCAD-36 | yes | 643.08 |
| E-MTAB-9841 | yes | 590.54 |
| E-CURD-6 | yes | 219.45 |
| E-MTAB-6701 | yes | 111.35 |
| E-HCAD-1 | yes | 88.03 |
| E-MTAB-8142 | yes | 84.03 |
| E-MTAB-10553 | yes | 54.61 |
| E-CURD-122 | yes | 40.19 |
| E-MTAB-8410 | yes | 39.77 |
| E-GEOD-135922 | yes | 35.44 |
| E-HCAD-10 | yes | 29.12 |
| E-CURD-112 | yes | 28.02 |
| E-HCAD-9 | yes | 26.20 |
| E-HCAD-11 | yes | 22.93 |
| E-MTAB-10042 | yes | 8.96 |
HPA expression
RNA tissue specificity: Group enriched
showing 60 of 75 HPA tissues / cells by nTPM:
| Tissue / cell | Axis | nTPM | Protein (IHC) |
|---|---|---|---|
| Lymph node | tissue | 265.6 | medium |
| Tonsil | tissue | 240.5 | medium |
| Spleen | tissue | 150.7 | low |
| Bone marrow | tissue | 140.1 | low |
| Thymus | tissue | 129.4 | |
| Appendix | tissue | 108.8 | medium |
| Urinary bladder | tissue | 39.2 | not detected |
| Stomach 1 | tissue | 30.6 | not detected |
| Rectum | tissue | 30.5 | not detected |
| Small intestine | tissue | 29.3 | not detected |
| Lung | tissue | 29.2 | not detected |
| Gallbladder | tissue | 24.9 | not detected |
| Colon | tissue | 23.3 | not detected |
| Duodenum | tissue | 19.3 | not detected |
| Liver | tissue | 18.5 | not detected |
| Breast | tissue | 17.5 | not detected |
| Salivary gland | tissue | 13.2 | not detected |
| Smooth muscle | tissue | 11.7 | not detected |
| Adipose tissue | tissue | 11.0 | not detected |
| Cervix | tissue | 9.6 | not detected |
| Esophagus | tissue | 7.9 | not detected |
| Prostate | tissue | 7.6 | not detected |
| Spinal cord | tissue | 7.3 | |
| Endometrium 1 | tissue | 6.3 | not detected |
| Corpus callosum | tissue | 6.2 | |
| Adrenal gland | tissue | 5.6 | not detected |
| Placenta | tissue | 5.4 | not detected |
| Fallopian tube | tissue | 5.4 | not detected |
| Medulla oblongata | tissue | 5.2 | |
| Substantia nigra | tissue | 5.2 | |
| Vagina | tissue | 4.8 | not detected |
| Midbrain | tissue | 4.8 | |
| Epididymis | tissue | 4.7 | not detected |
| Thyroid gland | tissue | 4.4 | not detected |
| Seminal vesicle | tissue | 4.1 | not detected |
| Olfactory bulb | tissue | 4.1 | |
| Heart muscle | tissue | 4.0 | not detected |
| Periaqueductal gray | tissue | 4.0 | |
| Thalamus | tissue | 3.7 | |
| Hypothalamus | tissue | 3.7 | |
| Pons | tissue | 3.6 | |
| Kidney | tissue | 3.6 | not detected |
| Septum | tissue | 3.6 | |
| Superior colliculi | tissue | 3.5 | |
| Skin 1 | tissue | 3.3 | not detected |
| Putamen | tissue | 3.3 | |
| Hippocampal formation | tissue | 3.3 | |
| Ventral forebrain | tissue | 3.3 | |
| Tongue | tissue | 3.2 | |
| Basal ganglia | tissue | 3.1 | not detected |
| Amygdala | tissue | 3.1 | |
| Testis | tissue | 2.7 | not detected |
| Skeletal muscle | tissue | 2.7 | not detected |
| Cerebellum | tissue | 2.7 | not detected |
| Entorhinal cortex | tissue | 2.7 | |
| Cerebral cortex | tissue | 2.6 | not detected |
| Ovary | tissue | 2.6 | not detected |
| Retrosplenial and cingulate cortex | tissue | 2.6 | |
| Retrosplenial cortex | tissue | 2.6 | |
| Temporal cortex | tissue | 2.6 |
Brain sub-regions (HPA Brain Atlas): detected in 186; highest nTPM — Dorsal spinal cord (7.3), Ventral spinal cord (6.9), Blood vessel (6.8), White matter (6.2), Lateral funiculus (white matter) (5.9).
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
Targeting CD48 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).
showing 30 of 31 miRNAs:
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-3163 | 100.00 | 77.23 | 8605 |
| HSA-MIR-5692A | 100.00 | 74.40 | 6850 |
| HSA-MIR-4262 | 100.00 | 73.26 | 3931 |
| HSA-MIR-196A-1-3P | 99.99 | 72.15 | 2772 |
| HSA-MIR-181D-5P | 99.99 | 73.04 | 2997 |
| HSA-MIR-181A-5P | 99.99 | 72.96 | 2995 |
| HSA-MIR-181B-5P | 99.99 | 72.97 | 2996 |
| HSA-MIR-181C-5P | 99.99 | 72.95 | 2996 |
| HSA-MIR-548AT-5P | 99.96 | 70.83 | 2666 |
| HSA-MIR-570-3P | 99.96 | 72.41 | 4910 |
| HSA-MIR-6508-5P | 99.92 | 70.67 | 2465 |
| HSA-MIR-3529-3P | 99.90 | 73.55 | 3045 |
| HSA-MIR-8067 | 99.86 | 69.59 | 2260 |
| HSA-MIR-6756-5P | 99.82 | 67.97 | 2466 |
| HSA-MIR-4668-5P | 99.79 | 70.58 | 3782 |
| HSA-MIR-4422 | 99.72 | 72.07 | 2908 |
| HSA-MIR-33A-3P | 99.70 | 70.27 | 3362 |
| HSA-MIR-6766-5P | 99.68 | 67.70 | 2325 |
| HSA-MIR-543 | 99.52 | 69.03 | 2595 |
| HSA-MIR-409-3P | 99.50 | 66.33 | 1192 |
| HSA-MIR-6083 | 99.47 | 68.73 | 2393 |
| HSA-MIR-3922-3P | 99.25 | 64.96 | 1136 |
| HSA-MIR-3176 | 99.25 | 64.35 | 954 |
| HSA-MIR-4291 | 99.20 | 68.88 | 2969 |
| HSA-MIR-3675-3P | 99.09 | 67.70 | 968 |
| HSA-MIR-4424 | 98.91 | 70.33 | 1145 |
| HSA-MIR-6755-3P | 98.61 | 66.90 | 834 |
| HSA-MIR-31-5P | 98.58 | 68.35 | 1239 |
| HSA-MIR-4483 | 98.09 | 64.12 | 1642 |
| HSA-MIR-3074-3P | 97.83 | 67.26 | 922 |
Functional genomics
gnomAD constraint: pLI 5.03e-07, LOEUF 1.31, missense Z -0.062 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD
Regional missense constraint (gnomAD RMC): no regional variation along ENST00000368046 — one region, missense o/e 1.07.
Literature-anchored findings (GeneRIF, showing 37)
- The Drosophila miR-959-962 Cluster Members Repress Toll Signaling to Regulate Antibacterial Defense during Bacterial Infection. (PMID:33477373)
- CM1-induced apoptosis is achieved via different initiation pathways, which are cell-type dependent (PMID:12072193)
- Signal-dependent adhesion of resting NK cells initiated by expression of ICAM-1 is greatly enhanced by coexpression of CD48, even in the absence of cytokines. (PMID:12496412)
- Engagement of natural killer (NK) cell receptor 2B4 by its counterreceptor, CD48, expressed on target cells leads to an inhibition in NK cytotoxicity independent of signaling lymphocytic activation molecule-associated protein (SAP) expression. (PMID:15356144)
- IL-18, IL-18 receptor alpha, and CD48 complex formation via glycosylphosphatidylinositol anchor glycan triggers binding to IL-18 receptor beta, and thereby induces intracellular signal transduction and IFN-gamma production. (PMID:15760905)
- Review of recent studies suggests an important role for interactions between 2B4 and CD48 in the course of T cell activation and proliferation (PMID:16081768)
- 2B4 (CD244) can stimulate NK cell cytotoxicity and cytokine production by interacting with NK cell expressed CD48 and adds CD48 to the growing number of activating NK cell receptors (PMID:16585556)
- CD48 is an interleukin (IL)-3-induced activating receptor on eosinophils and may be involved in promoting allergic inflammation. (PMID:16785501)
- CD48 is a CD2 and CD244 (2B4)-binding protein (PMID:16803907)
- In conclusion, we cannot confirm a role of human endogenous retrovirus-K18 superantigen polymorphisms or of the CD48 CA repeat for type 1 diabetes susceptibility. (PMID:16866884)
- findings indicate that FimH induces host cell signalling cascades that are involved in E. coli K1 invasion of human brain microvascular endothelial cells (HBMEC) and CD48 is a putative HBMEC receptor for FimH (PMID:17222190)
- the mechanism of signal transduction by CD244 is to regulate FYN kinase recruitment and/or activity and the outcome of CD48/CD244 interactions is determined by which other receptors are engaged. (PMID:17599905)
- CD2 functions as the master switch recruiting CD48 and Lck (PMID:19494291)
- The ligand (CD48) of the 2B4 receptor can exert both activating and inhibiting signals; natural killer (NK) cells might be at risk for self-killing were it not for the inhibiting signals generated by the 2B4-CD48 interaction. (PMID:20164429)
- Stimulation of CD48 induces rearrangement of signaling factors in lipid rafts, Lck-kinase activity, and tyrosine phosphorylation. (PMID:20833258)
- replication study of association of 2 SNPs in HERV-K18 and 19 tagSNPs in CD48 with schizophrenia (SZ)and type 2 diabetes (T2D) in patients with SZ in 2 Danish samples; no association was found with SZ or with T2D among individuals with SZ for any of the SNPs (PMID:22495247)
- Monocyte-induced natural killer cell dysfunction was markedly attenuated by blocking CD48 receptor 2B4 on NK cells, but not by blockade of NKG2D and NKp30. (PMID:23225218)
- Blockade of 2B4/CD48 interaction resulted in improvement in function via perforin expression and degranulation as measured by CD107a surface mobilization on HTLV-1 specific CD8+ T cells. (PMID:24505299)
- we propose that SLAMF2 engagement regulates adaptive immune responses (PMID:24670806)
- These data demonstrate the important role of CD48 in SA/exotoxins-eosinophil activating interactions that can take place during allergic responses and indicate CD48 as a novel therapeutic target for allergy and especially of AD. (PMID:25255823)
- Our data indicate sCD48 as a SEB-induced ‘decoy’ receptor derived from eosinophil and therefore as a potential anti-inflammatory tool in S. aureus-induced eosinophil inflammation often associated with allergy. (PMID:26836239)
- The present study provides further insights into the role of the 2B4-CD48 interaction in the fine regulation of CD8(+) T-cell effector function upon antigenic stimulation. (PMID:26860368)
- CD48 expression was increased in patients with a short disease duration compared to both controls and patients with longer disease duration. In patients with short disease duration, increased CD48 expression was associated with alveolar inflammation. (PMID:26926492)
- Data show that 2B4 not only can bind to CD48 in trans but also interacts with CD48 in cis by using the same binding interface. Also, the results demonstrated that constitutive phosphorylation of 2B4 occurs only in the presence of CD48, and that cis binding is sufficient to induce substantial levels of baseline phosphorylation. (PMID:27249817)
- mCD48 and sCD48 are differentially expressed in the peripheral blood of asthma patients of varying severity. sCD48 inhibits CD244-mediated eosinophil activation. These findings suggest that CD48 may play an important role in human asthma. (PMID:27859399)
- soluble CD48 levels were significantly elevated in patients with nonallergic asthma compared to control and to the allergic asthma cohort (PMID:30306094)
- immune receptor CD48 is overexpressed on MM cells together with SLAMF7, and that CD48 may be considered as an alternative target for treatment of MM in cases showing weak expression of SLAMF7. (PMID:31115879)
- this study demonstrates recurrent inflammatory disease caused by a heterozygous mutation in CD48 (PMID:31419545)
- CD48 mRNA expression was significantly lower in patients than in normal healthy individuals. (PMID:31922199)
- Human innate lymphoid cell precursors express CD48 that modulates ILC differentiation through 2B4 signaling. (PMID:33219153)
- sCD48 is elevated in non-allergic but not in allergic persistent rhinitis. (PMID:34477021)
- GDF15 induces immunosuppression via CD48 on regulatory T cells in hepatocellular carcinoma. (PMID:34489334)
- Elevated levels of sCD48 are inversely correlated with markers of disease activity in bullous pemphigoid. (PMID:36134505)
- Patients with coronavirus disease 2019 characterized by dysregulated levels of membrane and soluble cluster of differentiation 48. (PMID:36280100)
- Boosting of tau protein aggregation by CD40 and CD48 gene expression in Alzheimer’s disease. (PMID:36520044)
- Programmed Cell Death-1 (PD-1) anchoring to the GPI-linked co-receptor CD48 reveals a novel mechanism to modulate PD-1-dependent inhibition of human T cells. (PMID:36889184)
- CD48 suppresses proliferation and migration as an immune-related prognostic signature in the cervical cancer immune microenvironment. (PMID:37279525)
Cross-species orthologs
3 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | cd58 | ENSDARG00000098461 |
| mus_musculus | Cd48 | ENSMUSG00000015355 |
| rattus_norvegicus | Cd48 | ENSRNOG00000004737 |
Paralogs (9): SLAMF7 (ENSG00000026751), CD84 (ENSG00000066294), CD2 (ENSG00000116824), SLAMF1 (ENSG00000117090), CD244 (ENSG00000122223), LY9 (ENSG00000122224), SLAMF8 (ENSG00000158714), SLAMF9 (ENSG00000162723), SLAMF6 (ENSG00000162739)
Mouse-model phenotypes
Observed phenotypes of the mouse ortholog (MGI:88339) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 3 distinct phenotype terms.
| Mouse phenotype (MP) | Records |
|---|---|
| abnormal T cell activation | 1 |
| decreased T cell proliferation | 1 |
| increased CD4-positive, alpha-beta T cell number | 1 |
Genomic neighbors (locus context)
Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).
| Symbol | Type | Entrez |
|---|---|---|
| CD84-AS1 | ncRNA | 105371468 |
| SLAMF7 | protein-coding | 57823 |
| SLAMF1 | protein-coding | 6504 |
| CD84 | protein-coding | 8832 |
| LY9 | protein-coding | 4063 |
| CD244 | protein-coding | 51744 |
| SLAMF6 | protein-coding | 114836 |
Protein
Protein identifiers
CD48 antigen — P09326 (reviewed: P09326)
Alternative names: B-lymphocyte activation marker BLAST-1, BCM1 surface antigen, Leukocyte antigen MEM-102, SLAM family member 2, Signaling lymphocytic activation molecule 2, TCT.1
All UniProt accessions (2): A0A087X1S7, P09326
UniProt curated annotations — full annotation on UniProt →
Function. Glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein that interacts via its N-terminal immunoglobulin domain with cell surface receptors including CD244/2B4 or CD2 to regulate immune cell function and activation. Participates in T-cell signaling transduction by associating with CD2 and efficiently bringing the Src family protein kinase LCK and LAT to the TCR/CD3 complex. In turn, promotes LCK phosphorylation and subsequent activation. Induces the phosphorylation of the cytoplasmic immunoreceptortyrosine switch motifs (ITSMs) of CD244 initiating a series of signaling events that leads to the generation of the immunological synapse and the directed release of cytolytic granules containing perforin and granzymes by T-lymphocytes and NK-cells.
Subunit / interactions. Interacts with CD2. Interacts with CD244; this interaction is possible not only on different cells (trans interaction) but also on the same cell (cis interaction). Interacts with LCK.
Subcellular location. Cell membrane. Membrane raft. Secreted.
Tissue specificity. Widely expressed on all hematopoietic cells.
Induction. By IFN-alpha/beta and IFN-gamma both at the level of CD48 mRNA and cell surface expression.
Isoforms (2)
| UniProt ID | Names | Canonical? |
|---|---|---|
| P09326-1 | 1 | yes |
| P09326-2 | 2 |
RefSeq proteins (2): NP_001242959, NP_001769* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR003599 | Ig_sub | Domain |
| IPR007110 | Ig-like_dom | Domain |
| IPR013106 | Ig_V-set | Domain |
| IPR013783 | Ig-like_fold | Homologous_superfamily |
| IPR015631 | CD2/SLAM_rcpt | Family |
| IPR036179 | Ig-like_dom_sf | Homologous_superfamily |
Pfam: PF07686, PF13895
UniProt features (31 total): strand 9, glycosylation site 5, turn 3, splice variant 2, sequence variant 2, sequence conflict 2, domain 2, signal peptide 1, chain 1, disulfide bond 1, propeptide 1, helix 1, lipid moiety-binding region 1
Structure
Experimental structures (PDB)
1 structures by resolution:
| PDB | Title | Method | Resolution (Å) |
|---|---|---|---|
| 2EDO | Solution structure of the first ig-like domain from human CD48 antigen | SOLUTION NMR |
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-P09326-F1 | 83.20 | 0.61 |
Human Protein Atlas
Protein class: CD markers, Transporters, Accessory Factors Involved in Transport, Predicted membrane proteins, Predicted secreted proteins, Plasma proteins
Protein evidence: Evidence at protein level
Subcellular location (HPA, imaging): plasma membrane; cytosol; nucleoli fibrillar center
Antibody reliability (HPA): IH enhanced · IF approved
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (1)
| Type | Positions |
|---|---|
| Gpi-anchor amidated serine | 220 |
Disulfide bonds (1)
| Type | Positions |
|---|---|
| Disulfide bond | 154–196 |
Glycosylation sites (5)
| Type | Positions |
|---|---|
| N-linked (glcnac…) asparagine | 189, 40, 44, 104, 162 |
Function
Pathways and Gene Ontology
Reactome pathways
1 curated (TAS) of 2; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).
2 pathways:
| ID | Pathway | Evidence |
|---|---|---|
| R-HSA-202733 | Cell surface interactions at the vascular wall | curated |
| R-HSA-109582 | Hemostasis | — |
MSigDB gene sets: 315 (showing top):
VERHAAK_AML_WITH_NPM1_MUTATED_DN, WALLACE_PROSTATE_CANCER_RACE_UP, MCLACHLAN_DENTAL_CARIES_UP, MODULE_45, CROONQUIST_NRAS_SIGNALING_UP, WIELAND_UP_BY_HBV_INFECTION, GOLDRATH_ANTIGEN_RESPONSE, MODULE_75, FINAK_BREAST_CANCER_SDPP_SIGNATURE, DEURIG_T_CELL_PROLYMPHOCYTIC_LEUKEMIA_DN, MODULE_171, GOBP_NATURAL_KILLER_CELL_ACTIVATION, SANSOM_APC_TARGETS_DN, BROWN_MYELOID_CELL_DEVELOPMENT_DN, SABATES_COLORECTAL_ADENOMA_DN
GO Biological Process (5): defense response (GO:0006952), immune response (GO:0006955), natural killer cell activation (GO:0030101), signal transduction (GO:0007165), leukocyte activation (GO:0045321)
GO Molecular Function (2): receptor ligand activity (GO:0048018), protein binding (GO:0005515)
GO Cellular Component (6): plasma membrane (GO:0005886), membrane (GO:0016020), membrane raft (GO:0045121), extracellular exosome (GO:0070062), side of membrane (GO:0098552), extracellular region (GO:0005576)
Reactome top-level categories
1 top-level categories:
| Category | Pathways |
|---|---|
| Hemostasis | 1 |
GO top-level categories
20 GO namespaces:
| Category | Terms |
|---|---|
| cellular anatomical structure | 3 |
| immune system process | 2 |
| membrane | 2 |
| response to stress | 1 |
| response to stimulus | 1 |
| lymphocyte activation | 1 |
| cell communication | 1 |
| cellular process | 1 |
| signaling | 1 |
| regulation of cellular process | 1 |
| cellular response to stimulus | 1 |
| cell activation | 1 |
| signaling receptor binding | 1 |
| signal transduction | 1 |
| signaling receptor activator activity | 1 |
| binding | 1 |
| cell periphery | 1 |
| membrane microdomain | 1 |
| extracellular vesicle | 1 |
| leaflet of membrane bilayer | 1 |
Experimentally-supported GO annotations
GO terms backed by direct experimental evidence (ECO experimental codes) — 5 of 13 annotations. The rest are phylogenetic / computational / electronic (IEA).
5 experimentally-supported GO terms:
| GO term | NS | Evidence |
|---|---|---|
| natural killer cell activation | BP | direct assay |
| extracellular exosome | CC | high-throughput assay |
| membrane | CC | high-throughput assay |
| membrane raft | CC | direct assay |
| receptor ligand activity | MF | direct assay |
Protein interactions and networks
STRING
showing 15 of 2,226 interactions by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| CD48 | LY9 | Q9HBG7 | 914 |
| CD48 | CD84 | Q9UIB8 | 860 |
| CD48 | CD244 | Q9BZW8 | 860 |
| CD48 | CD2 | P06729 | 845 |
| CD48 | SLAMF6 | Q96DU3 | 807 |
| CD48 | KIT | P10721 | 806 |
| CD48 | MATK | P42679 | 799 |
| CD48 | FLT3 | P36888 | 779 |
| CD48 | SH2D1A | O60880 | 773 |
| CD48 | SLAMF7 | Q9NQ25 | 765 |
| CD48 | LCK | P06239 | 752 |
| CD48 | NCR1 | O76036 | 749 |
| CD48 | CD58 | P19256 | 748 |
| CD48 | CD34 | P28906 | 713 |
| CD48 | PTPRC | P08575 | 689 |
IntAct
Human interaction partners of CD48 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).
5 partners by confidence:
| Partner | Interaction type | MIscore | Records |
|---|---|---|---|
| CD244 | physical association | 0.790 | 5 |
| PRAP1 | association | 0.530 | 1 |
| POTEF | association | 0.350 | 1 |
| BXDC2 | physical association | 0.000 | 1 |
| EEF1D | physical association | 0.000 | 1 |
BioGRID (36 interactions; top human partners by supporting records): PRAP1 (Affinity Capture-MS; 3 records), ADAM21 (Affinity Capture-MS), BRIX1 (Two-hybrid), CBWD3 (Affinity Capture-MS), CD2 (Reconstituted Complex), CLSTN1 (Affinity Capture-MS), CTHRC1 (Affinity Capture-MS), EEF1D (Two-hybrid), FBXO2 (Affinity Capture-MS), GPR107 (Affinity Capture-MS), HSPA5 (Affinity Capture-MS), IGF1R (Affinity Capture-MS), LAMB1 (Affinity Capture-MS), LAMB2 (Affinity Capture-MS), LAMC1 (Affinity Capture-MS)
Ligand–receptor pairs (CellPhoneDB) (1)
Curated ligand–receptor partners (cell-cell communication), distinct from the protein–protein interactions above.
1 ligand–receptor pairs:
| Partner | This gene’s role | Signaling class |
|---|---|---|
| CD244 | ligand |
Disease & clinical
Genetic variants
Variant evidence for CD48: 55 ClinVar records (0 pathogenic / likely pathogenic); 5 GWAS associations.
ClinVar
55 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 38 |
| Likely benign | 4 |
| Benign | 7 |
SpliceAI
Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 19 predictions of 522):
| Position(s) | Effect | Δscore | Sites |
|---|---|---|---|
| 1:160711680–160711681 | donor_loss | 0.9900 | 5 |
| 1:160698232 | donor_gain | 0.9700 | |
| 1:160711680 | donor_loss | 0.9700 | |
| 1:160711693 | donor_gain | 0.9500 | |
| 1:160680045 | acceptor_gain | 0.9400 | |
| 1:160685051 | donor_gain | 0.9400 | |
| 1:160681380 | donor_gain | 0.9200 | |
| 1:160704387 | donor_gain | 0.9200 | |
| 1:160711682 | donor_loss | 0.9200 | |
| 1:160681469–160681470 | acceptor_loss | 0.8800 | 6 |
AlphaMissense
211 missense substitutions predicted likely pathogenic (of 1,594 scored), across 67 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:
| Residue | Likely-pathogenic substitutions | Mean am_pathogenicity | Max am_pathogenicity |
|---|---|---|---|
| D103 | 8 | 0.915 | 0.967 |
| C154 | 7 | 0.943 | 0.964 |
| C196 | 7 | 0.936 | 0.970 |
| W58 | 7 | 0.913 | 0.977 |
| W165 | 7 | 0.907 | 0.983 |
| F81 | 7 | 0.872 | 0.932 |
| C148 | 7 | 0.788 | 0.840 |
| N200 | 7 | 0.784 | 0.948 |
| C215 | 7 | 0.768 | 0.854 |
| F77 | 6 | 0.798 | 0.936 |
| V127 | 6 | 0.798 | 0.906 |
| Y107 | 5 | 0.932 | 0.976 |
| S203 | 5 | 0.844 | 0.931 |
| F59 | 5 | 0.796 | 0.819 |
| R84 | 5 | 0.772 | 0.884 |
| K65 | 5 | 0.762 | 0.891 |
| E68 | 5 | 0.591 | 0.609 |
| I66 | 4 | 0.792 | 0.887 |
| S105 | 4 | 0.735 | 0.758 |
| G92 | 4 | 0.694 | 0.806 |
HPA cancer prognostics
RNA cancer specificity: Low cancer specificity
Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.
2 prognostic cancer types:
| Cancer | Prognostic | p-value |
|---|---|---|
| Lung Adenocarcinoma (TCGA) | favorable | 0.000312 |
| Breast Invasive Carcinoma (TCGA) | favorable | 0.000581 |
Disease associations
OMIM: gene MIM:109530 | disease phenotypes:
Genomics England panels (PanelApp)
Clinical diagnostic gene panels including this gene (1 panels, 0 green/diagnostic-grade). Confidence: green = diagnostic, amber = moderate.
1 panels:
| Panel | Rating |
|---|---|
| Primary immunodeficiency or monogenic inflammatory bowel disease | amber |
GWAS associations
5 associations:
| Study | Trait | p-value |
|---|---|---|
| GCST006585_2236 | Blood protein levels | 5e-19 |
| GCST009597_136 | Multiple sclerosis | 6e-16 |
| GCST001725_36 | Inflammatory bowel disease | 7e-9 |
| GCST004861_6 | Itch intensity from mosquito bite | 2e-8 |
| GCST004068_43 | Venous thromboembolism adjusted for sickle cell variant rs77121243-T | 5e-7 |
EFO canonical traits (from GWAS)
1 canonical traits:
| EFO ID | Trait name |
|---|---|
| EFO:0008377 | mosquito bite reaction itch intensity measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (CPIC guideline: no)
CTD chemical–gene interactions
30 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| (+)-JQ1 compound | decreases expression | 4 |
| Nickel | increases expression | 2 |
| GSK-J4 | increases expression | 1 |
| terbufos | increases methylation | 1 |
| sodium arsenite | affects methylation | 1 |
| manganese chloride | increases expression | 1 |
| aflatoxin B2 | increases methylation | 1 |
| S-(1,2-dichlorovinyl)cysteine | affects response to substance, increases expression, affects cotreatment | 1 |
| 4-hydroxy-equilenin | increases expression | 1 |
| CGP 52608 | affects binding, increases reaction | 1 |
| cotylenin A | increases expression | 1 |
| Acetaminophen | decreases expression | 1 |
| Benzo(a)pyrene | increases methylation | 1 |
| Benzoates | increases expression | 1 |
| Carbamazepine | affects expression | 1 |
| Cisplatin | increases expression | 1 |
| Demecolcine | increases expression | 1 |
| Diuron | decreases expression | 1 |
| Dust | increases expression | 1 |
| Fonofos | increases methylation | 1 |
| Lipopolysaccharides | increases expression, affects response to substance, affects cotreatment | 1 |
| Manganese | increases expression | 1 |
| Methotrexate | decreases expression | 1 |
| Methyl Methanesulfonate | decreases expression | 1 |
| Parathion | increases methylation | 1 |
| Tretinoin | increases expression | 1 |
| Vincristine | increases expression | 1 |
| Antirheumatic Agents | decreases expression | 1 |
| Cadmium Chloride | increases expression | 1 |
| beta-Naphthoflavone | decreases expression | 1 |
Cellosaurus cell lines
2 cell lines: 2 cancer cell line
First 10 cell lines (id-ordered, not curated):
| Cellosaurus | Name | Category | Sex |
|---|---|---|---|
| CVCL_B7WI | Abcam Raji CD48 KO | Cancer cell line | Male |
| CVCL_B9X3 | Abcam THP-1 CD48 KO | Cancer cell line | Male |
Clinical trials (associated diseases)
Via MONDO — disease-level, not drug-specific.
Related Atlas pages
- Disease cohort memberships (association, not causation — diseases whose associated-gene cohort lists this gene; a subset are also under Associated diseases): venous thromboembolism